Board approves re-appointment of MD and Whole Time Director, each for three years
Mr. Swapnil Jatinbhai Shah re-appointed as Managing Director for three (3) consecutive years w.e.f. October 15, 2026.
By ScoutQuest · · 2 min read
- MD Re-appointment Term
- three (3) consecutive years w.e.f. October 15, 2026
- Whole Time Director Re-appointment Term
- three (3) consecutive years w.e.f. November 10, 2026
- Shareholder Approval
- subject to shareholder approval through a postal ballot
Leadership continuity at the top
The board of Senores Pharmaceuticals met on Tuesday, October 13, 2026 and approved two re-appointments of existing senior management.
- Mr. Swapnil Jatinbhai Shah (DIN: 05259821) re-appointed as Managing Director for a further period of three (3) consecutive years with effect from October 15, 2026, liable to retire by rotation.
- Mr. Chetan Bipinchandra Shah (DIN: 10381971) re-appointed as Whole Time Director for a further period of three (3) consecutive years with effect from November 10, 2026, liable to retire by rotation.
Both decisions were based on the recommendation of the Nomination and Remuneration Committee.
Shareholder approval still to come
- Both re-appointments are subject to the approval of shareholders, to be obtained through a postal ballot process.
Who the two directors are
- Mr. Swapnil Shah is the Promoter and Managing Director of the company, with over 15 years of experience in the pharmaceutical sector. He leads the company's overall functioning and is part of the core management team, with responsibility for product portfolio management, corporate strategy, business development and overall strategic management. He holds a master's degree in business administration from Hofstra University, New York and a bachelor's degree in chemical engineering from Nirma University, and is convenor of the pharma panel in the Confederation of Indian Industry (CII), Gujarat State Council.
- Mr. Chetan Shah is the Whole Time Director and Chief Operating Officer, with over 30 years of experience, of which 25 years is in the pharmaceutical industry. He is part of the core management team and is responsible for strategy planning, capital expenditure planning, capacity expansion, policy enforcement, mergers and acquisitions, supply chain for both domestic and international operations, manufacturing processes and automation, risk management and overall management information system. He was previously associated with Torrent Pharmaceuticals Limited and Cadila Pharmaceuticals Limited.
Both directors are stated to be not related inter-se to any other directors of the company, and neither is debarred from holding the office of director by virtue of any SEBI order or any other such authority.
How to read this
- These are re-appointments of individuals already holding these roles, so the news points to continuity in the leadership team rather than a change of hands.
- The new terms begin on future dates and both are conditional on shareholders approving them through a postal ballot, so the matter now moves to a shareholder vote.
Also from Senores Pharmaceuticals
Senores Q2 FY27 earnings conference call rescheduled to 04:00 P.M. IST on October 29, 2026
23 Oct 2026
Senores Pharmaceuticals to hold Q2 & H1 FY27 earnings conference call on October 29, 2026
22 Oct 2026
Board meeting on October 29, 2026 to approve Q2 and H1 results
22 Oct 2026
More numbers
- Term of re-appointment of Mr. Swapnil Jatinbhai Shah as Managing Directorthree (3) consecutive years
- Term of re-appointment of Mr. Chetan Bipinchandra Shah as Whole Time Directorthree (3) consecutive years
- Experience of Mr. Swapnil Jatinbhai Shah in the pharmaceutical sectorover 15 years
- Total experience of Mr. Chetan Bipinchandra Shahover 30 years
- Pharmaceutical industry experience of Mr. Chetan Bipinchandra Shah25 years
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.